SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
SAN DIEGO—In many regions, rheumatologists are scarce, and shortfalls will only increase. Panelists in the session, Telehealth: Can It Expand the Rheumatology Workforce?, held Nov. 6 during the 2017 ACR/ARHP Annual Meeting, believe techÂnology can help bridge the gap. The more specific term, telemedicine, “refers to clinical care delivered from a distance,” said John A….
Greetings, advocates! Your government is back to work after ending a brief government shutdown by passing a short-term continuing resolution (CR), which will keep the government running at current funding levels into February. At some point, it would be great for Congress to pass a budget (instead of a CR) and to enact bipartisan plans…
During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…
What initially strikes people about Christopher Adams, MD, FACP, FACR, is his passion for fairness. In 2015, he told readers of The Rheumatologist, “Patients often feel powerless to fight the system and advocate for themselves, and many of my patients felt they lacked a mechanism for addressing their concerns. That’s where we come in.” Dr….
When former ACR President Joseph Flood, MD, tapped Deborah Dyett Desir, MD, to volunteer for an ACR committee, he might have assumed that her preference would be to serve on the Committee on Rheumatologic Care or its Insurance Subcommittee. After all, Dr. Desir is in private practice at the Arthritis and Osteoporosis Center PC in…
Together our voice is heard; our influence is alive. In 2017, ACR members heard the call of the Rheumatology Strong campaign and joined the American Medical Association (AMA) in force, ensuring the College maintains its representation in the country’s largest—and arguably most influential—physician society. “We surpassed our minimum 1,000-member goal by a margin and are hopeful…
Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego last month, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. In coming issues, we…